Education
About Us
Working with TipRanks
Follow Us
Spyre Therapeutics (SYRE)
NASDAQ:SYRE
Total Valuation
Spyre Therapeutics has a market cap or net worth of $2.60B. The enterprise value is $532.42M.
Market Cap$2.60B
Enterprise Value$532.42M
Share Statistics
Spyre Therapeutics has 77,592,130 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding77,592,130
Owned by Insiders7.45%
Owned by Institutions44.12%
Financial Efficiency
Spyre Therapeutics’s return on equity (ROE) is -0.40 and return on invested capital (ROIC) is -37.63%.
Return on Equity (ROE)-0.40
Return on Assets (ROA)-0.34
Return on Invested Capital (ROIC)-37.63%
Return on Capital Employed (ROCE)-0.38
Revenue Per Employee0.00
Profits Per Employee-2.85M
Employee Count73
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Spyre Therapeutics is ―. Spyre Therapeutics’s PEG ratio is 0.06.
PE Ratio―
PS Ratio0.00
PB Ratio2.11
Price to Fair Value2.11
Price to FCF-6.96
Price to Operating Cash Flow-52.08
PEG Ratio0.06
Income Statement
In the last 12 months, Spyre Therapeutics had revenue of 0.00 and earned -208.02M in profits. Earnings per share was -3.18.
Revenue0.00
Gross Profit0.00
Operating Income-208.57M
Pretax Income-207.97M
Net Income-208.02M
EBITDA-207.97M
Earnings Per Share (EPS)-3.18
Cash Flow
In the last 12 months, operating cash flow was -161.87M and capital expenditures 0.00, giving a free cash flow of -161.87M billion.
Operating Cash Flow-161.87M
Free Cash Flow-161.87M
Free Cash Flow per Share-2.09
Dividends & Yields
Spyre Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.60
52-Week Price Change27.38%
50-Day Moving Average23.79
200-Day Moving Average17.98
Relative Strength Index (RSI)73.89
Average Volume (3m)677.78K
Important Dates
Spyre Therapeutics upcoming earnings date is Feb 26, 2026, TBA (Confirmed).
Last Earnings DateNov 4, 2025
Next Earnings DateFeb 26, 2026
Ex-Dividend Date―
Financial Position
Spyre Therapeutics as a current ratio of 11.26, with Debt / Equity ratio of 0.00%
Current Ratio11.26
Quick Ratio11.26
Debt to Market Cap0.00
Net Debt to EBITDA0.43
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Spyre Therapeutics has paid 51.00K in taxes.
Income Tax51.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Spyre Therapeutics EV to EBITDA ratio is -4.83, with an EV/FCF ratio of -6.39.
EV to Sales0.00
EV to EBITDA-4.83
EV to Free Cash Flow-6.39
EV to Operating Cash Flow-6.39
Balance Sheet
Spyre Therapeutics has $486.20M in cash and marketable securities with $0.00 in debt, giving a net cash position of $486.20M billion.
Cash & Marketable Securities$486.20M
Total Debt$0.00
Net Cash$486.20M
Net Cash Per Share$6.27
Tangible Book Value Per Share$11.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Spyre Therapeutics is $56.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$56.50
Price Target Upside67.76% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast-123.65%